Ken Griffin
BIOSW

Ken Griffin’s BioPlus Acquisition Corp. Warrants BIOSW Stock Holding History

Ken Griffin’s Portfolio BIOSW Stock Details BIOSW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-375,000
Closed -$83K – 14534
2022
Q1 		$83K Buy
+375,000
New +$97.4K ﹤0.01% 12453

Other funds holding BIOSW

MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
RCM
Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.33B AUM 1.18% 1-Year Est. Return
CS
Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.21% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.02% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 12.96% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
SCM
Shaolin Capital Management Miami, Florida $2.71B AUM 64.57% 1-Year Est. Return
MI
MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 76.63% 1-Year Est. Return

Ken Griffin's BIOSW Position: Q2 2022 in Review

Ken Griffin sold out of BioPlus Acquisition Corp. Warrants (BIOSW) in Q2 2022, closing a stake of 375,000 shares — an estimated $83K sold.

Ken Griffin first reported a position in BIOSW in Q1 2022 and held it in 1 quarter. The position peaked at $83K in Q1 2022. 51 funds tracked by Wall St. Rank hold BIOSW as of Q2 2022.

  • Ken Griffin reported no remaining BioPlus Acquisition Corp. Warrants position as of Q2 2022 after selling out during the quarter.
  • Ken Griffin sold 375,000 BioPlus Acquisition Corp. Warrants shares in Q2 2022, an estimated $83K.
  • Ken Griffin first reported a position in BioPlus Acquisition Corp. Warrants in Q1 2022 and held it in 1 quarter.
  • Ken Griffin's BioPlus Acquisition Corp. Warrants position peaked at $83K in Q1 2022.
  • 51 funds tracked by Wall St. Rank held BioPlus Acquisition Corp. Warrants as of Q2 2022.

Based on Citadel Advisors's 13F filing for Q2 2022, filed 15 Aug 2022.